Abstract
Platelets from 6 out of 10 patients with myeloproliferative disorders showed only a single reversible wave of aggregation when challenged with platelet activating factor (PAF). Preexposure to subthreshold concentrations of adrenaline resulted in a full irreversible response to PAF. Aspirin, however, removed this synergism. In the remaining 4 patients, PAF induced a full response but aspirin abolished the synergism with adrenaline in 2 of them. In platelets from all controls aspirin failed to abolish the synergism between PAF and adrenaline. It is suggested that patients with myeloproliferative disorders lack – to varying degrees – an aspirin-independent mechanism which amplifies the primary response to PAF. Such a mechanism could involve the products of arachidonic acid metabolism catalyzed by lipoxygenase.
| Original language | English |
|---|---|
| Pages (from-to) | 27-33 |
| Number of pages | 7 |
| Journal | Pathophysiology of Haemostasis and Thrombosis |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1986 |
Fingerprint
Keywords
- Aspirin
- Cyclo-oxygenase
- Lipoxygenase
- Myeloproliferative disorders
- Platelet activating factor
- Platelet aggregation
ASJC Scopus subject areas
- Hematology
- Physiology (medical)
Cite this
Defective platelet aggregation induced by platelet activating factor in myeloproliferative disorders : Deficiency of an aspirin-independent mechanism? / Vie Ro, Piera; Cortelazzo, Sergio; Bar Bu I, Tiziano; De Gaetano, Giovanni.
In: Pathophysiology of Haemostasis and Thrombosis, Vol. 16, No. 1, 1986, p. 27-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Defective platelet aggregation induced by platelet activating factor in myeloproliferative disorders
T2 - Deficiency of an aspirin-independent mechanism?
AU - Vie Ro, Piera
AU - Cortelazzo, Sergio
AU - Bar Bu I, Tiziano
AU - De Gaetano, Giovanni
PY - 1986
Y1 - 1986
N2 - Platelets from 6 out of 10 patients with myeloproliferative disorders showed only a single reversible wave of aggregation when challenged with platelet activating factor (PAF). Preexposure to subthreshold concentrations of adrenaline resulted in a full irreversible response to PAF. Aspirin, however, removed this synergism. In the remaining 4 patients, PAF induced a full response but aspirin abolished the synergism with adrenaline in 2 of them. In platelets from all controls aspirin failed to abolish the synergism between PAF and adrenaline. It is suggested that patients with myeloproliferative disorders lack – to varying degrees – an aspirin-independent mechanism which amplifies the primary response to PAF. Such a mechanism could involve the products of arachidonic acid metabolism catalyzed by lipoxygenase.
AB - Platelets from 6 out of 10 patients with myeloproliferative disorders showed only a single reversible wave of aggregation when challenged with platelet activating factor (PAF). Preexposure to subthreshold concentrations of adrenaline resulted in a full irreversible response to PAF. Aspirin, however, removed this synergism. In the remaining 4 patients, PAF induced a full response but aspirin abolished the synergism with adrenaline in 2 of them. In platelets from all controls aspirin failed to abolish the synergism between PAF and adrenaline. It is suggested that patients with myeloproliferative disorders lack – to varying degrees – an aspirin-independent mechanism which amplifies the primary response to PAF. Such a mechanism could involve the products of arachidonic acid metabolism catalyzed by lipoxygenase.
KW - Aspirin
KW - Cyclo-oxygenase
KW - Lipoxygenase
KW - Myeloproliferative disorders
KW - Platelet activating factor
KW - Platelet aggregation
UR - http://www.scopus.com/inward/record.url?scp=84940635236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940635236&partnerID=8YFLogxK
U2 - 10.1159/000215266
DO - 10.1159/000215266
M3 - Article
AN - SCOPUS:84940635236
VL - 16
SP - 27
EP - 33
JO - Pathophysiology of Haemostasis and Thrombosis
JF - Pathophysiology of Haemostasis and Thrombosis
SN - 1424-8832
IS - 1
ER -